Limits...
Effects of Folic Acid on Secretases Involved in A β Deposition in APP/PS1 Mice

View Article: PubMed Central - PubMed

ABSTRACT

Alzheimer’s disease (AD) is the most common type of dementia. Amyloid-β protein (Aβ) is identified as the core protein of neuritic plaques. Aβ is generated by the sequential cleavage of the amyloid precursor protein (APP) via the APP cleaving enzyme (α-secretase, or β-secretase) and γ-secretase. Previous studies indicated that folate deficiency elevated Aβ deposition in APP/PS1 mice, and this rise was prevented by folic acid. In the present study, we aimed to investigate whether folic acid could influence the generation of Aβ by regulating α-, β-, and γ-secretase. Herein, we demonstrated that folic acid reduced the deposition of Aβ42 in APP/PS1 mice brain by decreasing the mRNA and protein expressions of β-secretase [beta-site APP-cleaving enzyme 1 (BACE1)] and γ-secretase complex catalytic component—presenilin 1 (PS1)—in APP/PS1 mice brain. Meanwhile, folic acid increased the levels of ADAM9 and ADAM10, which are important α-secretases in ADAM (a disintegrin and metalloprotease) family. However, folic acid has no impact on the protein expression of nicastrin (Nct), another component of γ-secretase complex. Moreover, folic acid regulated the expression of miR-126-3p and miR-339-5p, which target ADAM9 and BACE1, respectively. Taken together, the effect of folic acid on Aβ deposition may relate to making APP metabolism through non-amyloidogenic pathway by decreasing β-secretase and increasing α-secretase. MicroRNA (miRNA) may involve in the regulation mechanism of folic acid on secretase expression.

No MeSH data available.


Related in: MedlinePlus

Folate stimulated ADAM9 and ADAM10 expression in APP/PS1 mice. The mRNA/protein levels of ADAM9 and ADAM10 in the brains of APP/PS1 mice were detected by qRT-PCR/Western blot analysis. Representative immunoblotting images of ADAM9 and ADAM10 are shown. Quantitative analysis revealed that the 120 μg/kg folic acid treatment led to up-regulation of ADAM9 (A–C) and ADAM10 (D–F). Folate deficiency led to down-regulation of ADAM9 and ADAM10. The 600 μg/kg folic acid treatment only up-regulated ADAM9, but did not change ADAM10 level; total α-secretase activity was reduced in the deficiency group and was increased in both 120 μg/kg and 600 μg/kg groups (G). The data were expressed as means ± SD values, n = 6 animals/group. a: p < 0.05 versus the control group.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5037541&req=5

nutrients-08-00556-f002: Folate stimulated ADAM9 and ADAM10 expression in APP/PS1 mice. The mRNA/protein levels of ADAM9 and ADAM10 in the brains of APP/PS1 mice were detected by qRT-PCR/Western blot analysis. Representative immunoblotting images of ADAM9 and ADAM10 are shown. Quantitative analysis revealed that the 120 μg/kg folic acid treatment led to up-regulation of ADAM9 (A–C) and ADAM10 (D–F). Folate deficiency led to down-regulation of ADAM9 and ADAM10. The 600 μg/kg folic acid treatment only up-regulated ADAM9, but did not change ADAM10 level; total α-secretase activity was reduced in the deficiency group and was increased in both 120 μg/kg and 600 μg/kg groups (G). The data were expressed as means ± SD values, n = 6 animals/group. a: p < 0.05 versus the control group.

Mentions: As shown in Figure 2A–C, there was significant difference between four groups for ADAM9 expression (F[3,20] = 9.098, p < 0.05 for mRNA, F[3,20] = 31.4, p < 0.05 for protein). Compared to the control group the expression of ADAM9 mRNA and protein significantly decreased in the deficiency group, and increased in both the 120 μg/kg and 600 μg/kg groups. There was no difference between those two administration groups.


Effects of Folic Acid on Secretases Involved in A β Deposition in APP/PS1 Mice
Folate stimulated ADAM9 and ADAM10 expression in APP/PS1 mice. The mRNA/protein levels of ADAM9 and ADAM10 in the brains of APP/PS1 mice were detected by qRT-PCR/Western blot analysis. Representative immunoblotting images of ADAM9 and ADAM10 are shown. Quantitative analysis revealed that the 120 μg/kg folic acid treatment led to up-regulation of ADAM9 (A–C) and ADAM10 (D–F). Folate deficiency led to down-regulation of ADAM9 and ADAM10. The 600 μg/kg folic acid treatment only up-regulated ADAM9, but did not change ADAM10 level; total α-secretase activity was reduced in the deficiency group and was increased in both 120 μg/kg and 600 μg/kg groups (G). The data were expressed as means ± SD values, n = 6 animals/group. a: p < 0.05 versus the control group.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5037541&req=5

nutrients-08-00556-f002: Folate stimulated ADAM9 and ADAM10 expression in APP/PS1 mice. The mRNA/protein levels of ADAM9 and ADAM10 in the brains of APP/PS1 mice were detected by qRT-PCR/Western blot analysis. Representative immunoblotting images of ADAM9 and ADAM10 are shown. Quantitative analysis revealed that the 120 μg/kg folic acid treatment led to up-regulation of ADAM9 (A–C) and ADAM10 (D–F). Folate deficiency led to down-regulation of ADAM9 and ADAM10. The 600 μg/kg folic acid treatment only up-regulated ADAM9, but did not change ADAM10 level; total α-secretase activity was reduced in the deficiency group and was increased in both 120 μg/kg and 600 μg/kg groups (G). The data were expressed as means ± SD values, n = 6 animals/group. a: p < 0.05 versus the control group.
Mentions: As shown in Figure 2A–C, there was significant difference between four groups for ADAM9 expression (F[3,20] = 9.098, p < 0.05 for mRNA, F[3,20] = 31.4, p < 0.05 for protein). Compared to the control group the expression of ADAM9 mRNA and protein significantly decreased in the deficiency group, and increased in both the 120 μg/kg and 600 μg/kg groups. There was no difference between those two administration groups.

View Article: PubMed Central - PubMed

ABSTRACT

Alzheimer&rsquo;s disease (AD) is the most common type of dementia. Amyloid-&beta; protein (A&beta;) is identified as the core protein of neuritic plaques. A&beta; is generated by the sequential cleavage of the amyloid precursor protein (APP) via the APP cleaving enzyme (&alpha;-secretase, or &beta;-secretase) and &gamma;-secretase. Previous studies indicated that folate deficiency elevated A&beta; deposition in APP/PS1 mice, and this rise was prevented by folic acid. In the present study, we aimed to investigate whether folic acid could influence the generation of A&beta; by regulating &alpha;-, &beta;-, and &gamma;-secretase. Herein, we demonstrated that folic acid reduced the deposition of A&beta;42 in APP/PS1 mice brain by decreasing the mRNA and protein expressions of &beta;-secretase [beta-site APP-cleaving enzyme 1 (BACE1)] and &gamma;-secretase complex catalytic component&mdash;presenilin 1 (PS1)&mdash;in APP/PS1 mice brain. Meanwhile, folic acid increased the levels of ADAM9 and ADAM10, which are important &alpha;-secretases in ADAM (a disintegrin and metalloprotease) family. However, folic acid has no impact on the protein expression of nicastrin (Nct), another component of &gamma;-secretase complex. Moreover, folic acid regulated the expression of miR-126-3p and miR-339-5p, which target ADAM9 and BACE1, respectively. Taken together, the effect of folic acid on A&beta; deposition may relate to making APP metabolism through non-amyloidogenic pathway by decreasing &beta;-secretase and increasing &alpha;-secretase. MicroRNA (miRNA) may involve in the regulation mechanism of folic acid on secretase expression.

No MeSH data available.


Related in: MedlinePlus